DUBLIN, Aug. 10, 2015 /PRNewswire/ --
- Second quarter revenues of $735 million
- Second quarter reported $0.49 diluted (GAAP) loss per share from continuing operations and $1.08 adjusted diluted EPS from continuing operations
- U.S. Branded Pharmaceuticals second quarter revenue increase of 27 percent primarily attributable to the acquisition of Auxilium Pharmaceuticals
- U.S. Generic Pharmaceuticals continues strong growth in second quarter with 24 percent revenue increase oversecond quarter 2014
- International Pharmaceuticals second quarter results on-track and aligned with Company expectations
- Affirms revenue and adjusted diluted EPS guidance from continuing operations for full year 2015
Endo International plc (NASDAQ: ENDP) (TSX: ENL) today reported second quarter 2015 financial results, including:
- Revenues of $735 million, a 24 percent increase compared to second quarter 2014 revenues of $593 million, including new product revenue from 2014 and 2015 strategic M&A transactions.
- Reported loss from continuing operations of $91 million compared to second quarter 2014 reported income from continuing operations of $41 million.
- Adjusted income from continuing operations of $204 million, a 39 percent increase compared to second quarter 2014 adjusted income from continuing operations of $147 million.
- Reported diluted loss per share from continuing operations of $0.49 compared to second quarter 2014 reported diluted earnings per share from continuing operations of $0.25.
- Adjusted diluted earnings per share from continuing operations of $1.08 compared to second quarter 2014 adjusted diluted earnings per share from continuing operations of $0.89.
- Adjusted diluted shares for the second quarter 2015 include the weighted average of approximately 28 million shares issued in June 2015 as part of the financing to fund the pending acquisition of Par Pharmaceutical. Adjusted diluted earnings per share for the second quarter 2015 excluding the effect of these additional shares would have been $1.12.
“Our diversified business delivered strong financial results for the quarter and demonstrated the value that we expect to create through the continued execution of our strategy,” said Rajiv De Silva, President and CEO of Endo. “We are close to completing the integration planning for our acquisition of Par and we remain excited by the strategic expansion of our product portfolio, R&D pipeline and long-term growth profile that the Par assets and Par talent joining Endo are expected to help provide.
To read full press release, please click here.
Help employers find you! Check out all the jobs and post your resume.
